The NovaScan Difference

NovaScan has fundamentally advanced electrical impedance–based cancer assessment.

By identifying and exploiting the Cole relaxation frequency—a biophysical parameter that shifts by orders of magnitude with malignant transformation—NovaScan delivers a cancer signal that is both highly specific and independent of tissue mass. Unlike conventional impedance metrics, there is minimal overlap between benign and malignant tissue.

NovaScan combines this novel biophysical insight with high-frequency measurement capability and AI/ML-driven analysis, enabled by proprietary blocking IP that overcomes parasitic effects at clinically relevant frequencies. The result is a high-accuracy, low-cost, compact platform for point-of-care cancer assessment.